Abstract
Twenty-four patients with advanced cancer not reacting to conventional therapy were treated with 97 courses of i.v. MER (methanol extraction residue of BCG). MER was administered by i.v. infusion over a 4-h period, twice a week, in dosages varying from 0.05 mg to 1.25 mg. The skin reactivity to 5 recall antigens was evaluated in the patients. All patients except 4 were anergic. Twelve patients had no side-effects. Anergic patients had less side-effects than ergic patients. The side-effects recorded in the others were fever, chills, vomiting and tachycardia. The reaction subsided within 24 h after treatment and was tolerable for most patients. In 2 patients an objective improvement was observed. No changes in cutaneous reactivity, renal and hepatic functions were found. A significant increase in peripheral leucocyte count was noted in two patients and slight a increase in the remainder.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baldwin R. W., Pimm M. V. BGG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer. 1973 Sep 15;12(2):420–427. doi: 10.1002/ijc.2910120213. [DOI] [PubMed] [Google Scholar]
- Band P. R., Jao-King C., Urtasun R. C., Haraphongse M. Phase I study of corynebacterium parvum in patients with solid tumors. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1139–1145. [PubMed] [Google Scholar]
- Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer. N Engl J Med. 1974 Jun 27;290(26):1458–1469. doi: 10.1056/NEJM197406272902605. [DOI] [PubMed] [Google Scholar]
- Cheng V. S., Suit H. D., Wang C. C., Cummings C. Nonspecific immunotherapy by Corynebacterium parvum: phase I toxicity study in 12 patients with advanced cancer. Cancer. 1976 Apr;37(4):1687–1695. doi: 10.1002/1097-0142(197604)37:4<1687::aid-cncr2820370412>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
- Fisher B., Rubin H., Sartiano G., Ennis L., Wolmark N. Observations following Corynebacterium parvum administration to patients with advanced malignancy. a phase I study. Cancer. 1976 Jul;38(1):119–130. doi: 10.1002/1097-0142(197607)38:1<119::aid-cncr2820380121>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
- Mansell P. W. Letter: Reactions to BCG. JAMA. 1973 Dec 24;226(13):1570–1571. doi: 10.1001/jama.1973.03230130058031. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Ritts R. E., Jr, Schutt A. J., Hahn R. G. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer. Cancer Res. 1975 Nov;35(11 Pt 1):3075–3083. [PubMed] [Google Scholar]
- Muggleton P. W., Prince G. H., Hilton M. L. Effect of intravenous B.C.G. in guineapigs and pertinence to cancer immunotherapy in man. Lancet. 1975 Jun 21;1(7921):1353–1355. doi: 10.1016/s0140-6736(75)92261-8. [DOI] [PubMed] [Google Scholar]
- Robinson E., Bartal A., Cohen Y., Haasz R. A preliminary report on the effects of methanol extraction residue of BCG (MER) on cancer patients. Br J Cancer. 1975 Jul;32(1):1–4. doi: 10.1038/bjc.1975.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]